An intravenous GnRH study reported an initial plasma half-disappearance time of about 5.5–8 minutes in healthy participants and longer values (12–16.5 minutes) in chronic renal failure, where metabolic clearance was also markedly lower (about 631 mL/min versus about 1,640 mL/min in healthy subjects). A later, slower phase was also observed; this is not a universal half-life for all gonadorelin formulations.[1]
- Intravenous physiological studies cannot determine pharmacokinetics of an uncharacterized subcutaneous product.
- A targeted 2026-09-09 search for a subcutaneous gonadorelin human pharmacokinetic study found no matching PubMed record; this remains a genuine evidence gap, not a finding of equivalence to the intravenous data.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.
· Freshly reread the abstract via NCBI E-utilities; added the metabolic-clearance-rate figures and ran a targeted search for a subcutaneous PK study (none found). No qualified clinical review.